Online inquiry

IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4850MR)

This product GTTS-WQ4850MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SDC1 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001006946.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6382
UniProt ID P18827
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4850MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9703MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ3552MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ695MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ1952MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ6691MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ613MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ1808MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ9631MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW